Embodiments of the disclosure provide a method for determining beginning blood volume of a patient during dialysis (e.g., hemodialysis). Ultrafiltration rates are determined at different time stamps during dialysis by obtaining a blood flowrate measurement and hematocrit measurements at input port and output port of a dialyzer connected to the patient. The flowrate and hematocrit measurements are used to determine fluid removed from the patient during dialysis. The ultrafiltration rates and fluid removed from the patient are used to determine the beginning blood volume of the patient.

Methods, apparatuses, and systems for determining patient dialysis profiles, for example, of peritoneal transport status or disease progression, are described. For example, in one embodiment, a method of determining a patient profile of a dialysis patient may include obtaining a volume of fluid associated with the dialysis patient, generating patient information via fluorescence analysis of the patient fluid, and determining the patient profile based on evaluating the patient information with a profile library, the patient profile comprising at least one of a peritoneal transport status classification or a disease progression. Other embodiments are described.

A renal failure blood therapy system includes a renal failure blood therapy machine, concentration levels for each of a plurality of solutes removed from a patient's blood at each of the multiple times, a display device configured to display for selection at least one removed blood solute from the plurality of removed blood solutes, and a device programmed to (i) estimate at least one renal failure blood therapy patient parameter using the determined concentration levels for the at least one selected removed blood solute, (ii) determine a plurality of acceptable renal failure blood therapy treatments that meet a predetermined removed blood solute clearance for the at least one selected removed blood solute using the at least one renal failure blood therapy patient parameter, and (iii) enable selection of at least one of the plurality of acceptable renal failure blood therapy treatments for operation at the renal failure blood therapy machine.

An extracorporeal blood treatment apparatus is provided comprising a filtration unit connected to a blood circuit and to a dialysate circuit, a preparation device for preparing and regulating the composition of the dialysis fluid; a control unit is configured for setting a sodium concentration value for the dialysis fluid in the dialysis supply line at a set point based on the physician prescription; starting from the initial patient plasma conductivity, estimated at the beginning of the treatment, and based on the target plasma conductivity/sodium concentration which is equivalent to the dialysate conductivity/sodium concentration prescribed, the control unit determines the minimum constant gradient between dialysis fluid and plasma conductivity/concentration to be maintained during treatment to achieve the conductivity/concentration target in the patient plasma at the end of the session.

The present invention relates to an apparatus for an extracorporeal blood treatment having an extracorporeal blood circuit in which a dialyzer is arranged and having a dialyzate circuit, wherein the blood circuit is in fluid communication with a first chamber and the dialyzate circuit is in fluid communication with a second chamber of the dialyzer, and wherein the two chambers are separated from one another by a semipermeable membrane, with a dialyzate pump for a conveying of the dialysis solution being present in the dialyzate circuit, wherein the apparatus has a control unit that is configured to operate the apparatus in a first phase and in a second phase following the first phase, wherein the dialyzate pump is operated with a smaller flow rate in the first phase than in the second phase and/or wherein the dialyzate pump conveys a dialysis solution in the first phase that is of a higher concentration with respect to at least one component than in the second phase.

A remote service is implemented to automatically aggregate data across hemodialysis patients and hemodialysis patients and determine updated treatment options for patients to increase well-being and optimize performance of the hemodialysis machines. Patients or caregivers operating a hemodialysis machine or a local or remote user computing device associated with the hemodialysis machine can provide feedback regarding the patient's well-being to the remote service. The feedback can be provided at any of one or more times pre-treatment, during treatment, or post-treatment. Furthermore, the hemodialysis machine can be configured with one or more sensors that transmit data pertaining to device state of the hemodialysis machine, such as information about blood, dialysate used, saline solution, pump pressure, air trap and air detector, hemodialysis machine information (e.g., make and model), etc.

Certain aspects of the present disclosure provide a monitoring system comprising a continuous analyte sensor configured to generate analyte measurements associated with analyte levels of a patient, and a sensor electronics module coupled to the continuous analyte sensor and configured to receive and process the analyte measurements.

Systems, methods, and devices model, identify, and predict effects of dialysis on drugs and chemical substances in patients. The systems estimate and determine effects of dialysis on elutes and drugs and solve problems with prior systems in determining effects of dialysis on drugs and dosages, especially the removal of target substances from the blood of patients during dialysis. Drug and medicine dosage adjustments for patients undergoing dialysis are made by considering the dialysis systems, patients, and drug variables and the extent to which they affect drug removal. Patients receive proper dosing by accounting for the effects of their dialysis. Systems and methods include a combination of ex vivo simulated treatments and in-silico modeling and simulation. The effects of dialysis are estimated and determined for various drugs and dosages. A reliable and effective surrogate for performing studies on patients provides guidance for use of the drugs in dialysis patients.

Techniques and apparatuses for access recirculation of a patient during dialysis treatment are described. In one embodiment, for example, an apparatus may include at least one memory, and logic coupled to the at least one memory. The logic may be configured to determine a first hemoglobin concentration for a dialysis system, determine a change in an ultrafiltration rate, determine a second hemoglobin concentration modified due to the change in the ultrafiltration rate based on a dialysis system model of the dialysis system, and determine an access recirculation value for the dialysis system. Other embodiments are described.

A system and method for balancing flows of renal replacement fluid is disclosed. The method uses pressure controls and pressure sensing devices to more precisely meter and balance the flow of fresh dialysate and spent dialysate. The balancing system may use one or two balancing devices, such as a balance tube, a tortuous path, or a balance chamber.